Inovio Pharmaceuticals Investors: Class Action Lawsuit and Lead Plaintiff Deadline
NEW YORK, March 6, 2026 – Rosen Law Firm, a global investor rights law firm, is encouraging purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, to secure legal counsel before the April 7, 2026, lead plaintiff deadline in a securities class action lawsuit.
What Investors Should Know
If you purchased Inovio securities during the specified “Class Period,” you may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement. A class action lawsuit has already been filed.
Details of the Lawsuit
The lawsuit alleges that defendants made false and/or misleading statements and/or failed to disclose critical information regarding Inovio Pharmaceuticals, including:
- Deficiencies in the manufacturing process for Inovio’s CELLECTRA device.
- The unlikelihood of submitting the INO-3107 Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) by the second half of 2024.
- Insufficient data to support the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review.
- An overstatement of INO-3107’s overall regulatory and commercial prospects.
The suit claims that when the true details became public, investors suffered damages.
What to Do Next
If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. A lead plaintiff represents other class members in directing the litigation. Investors are not required to serve as lead plaintiff to potentially share in any future recovery.
To join the Inovio class action, visit https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq., toll-free at 866-767-3653, or email case@rosenlegal.com for more information.
Why Choose Rosen Law Firm?
Rosen Law Firm emphasizes its experience and track record in securities class actions. The firm highlights its success in achieving the largest ever securities class action settlement against a Chinese Company and its consistent ranking among top firms in the field, including being ranked No. 1 by ISS Securities Class Action Services in 2017. They caution investors to select qualified counsel with a proven history of success, noting that some firms act merely as intermediaries.
About Rosen Law Firm
Rosen Law Firm represents investors globally, specializing in securities class actions and shareholder derivative litigation. The firm has recovered hundreds of millions of dollars for investors and has received recognition from legal publications like Lawdragon and Super Lawyers. Founding partner Laurence Rosen was named a Titan of Plaintiffs’ Bar by Law360 in 2020.
Significant Disclaimer
No class has been certified. Until certification, you are not represented by counsel unless you retain one. You may choose your own counsel or remain an absent class member. Your ability to share in any potential recovery is not dependent on serving as lead plaintiff.
Follow Rosen Law Firm:
This is attorney advertising. Prior results do not guarantee a similar outcome.
Contact Information
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com
Related reading